Poor
Mostly Unaligned
Patient Risk:
Moderate
Summary
The AI response makes numerous medication- and dosing-related claims that are not supported by the provided FDA label excerpts (e.g., regimen adequacy, prednisone co-prescribing without specifying schedule, and “switching products mid-treatment”). It also includes many non-label pricing statements that cannot be verified against the labeling and therefore reduce overall label-alignment.
Category Scores
Accurate Statements
Generic abiraterone pricing can vary by country.
Not addressed in provided FDA prescribing information excerpts.
Generic abiraterone pricing can vary by pharmacy.
Not addressed in provided FDA prescribing information excerpts.
Generic abiraterone pricing can vary by dose (typically tablets).
Not addressed in provided FDA prescribing information excerpts.
Generic abiraterone is generally less expensive than brand-name abiraterone (Zytiga).
Not addressed in provided FDA prescribing information excerpts.
Prescribers may adjust the abiraterone dose regimen.
The label includes dose modification guidance (e.g., hepatic impairment, hepatotoxicity interruption/restart; CYP3A4 inducer dosing frequency adjustment), but does not broadly state “may adjust” in general terms.
Confirming with a prescriber/pharmacist should include ensuring the active ingredient and dosing instructions match the current regimen.
Supported in part by label requirement that patients receive abiraterone acetate tablets with prednisone and administration/dosing instructions; however, the phrase is not explicitly stated.
Confirming with a prescriber/pharmacist should include ensuring the same strength and dose schedule are provided.
Partially supported by label dose described as 1,000 mg (four 250 mg tablets) and specific administration/dose schedules; not explicitly stated as a recommendation to confirm with prescriber/pharmacist.
Unsupported Statements
A common abiraterone regimen for prostate cancer is 4 tablets per day.
The label specifies 1,000 mg (four 250 mg tablets) orally once daily, not “four tablets per day” as a general common regimen without context. The AI statement is incomplete/misleading relative to labeled dosing schedules and indication-specific prednisone co-administration.
Prescribers may adjust the abiraterone dose regimen.
Only specific, label-defined adjustments are provided (e.g., hepatic impairment/hepatotoxicity/CYP3A4 inducer); the broad claim is not explicitly supported.
A prednisone regimen is commonly co-prescribed with abiraterone.
The label requires prednisone co-administration for indicated use, but the claim uses generalized language (“commonly”) and does not reflect label-specific prednisone dosing frequency by indication (CRPC vs high-risk CSPC).
Switching products mid-treatment is usually possible.
No label excerpt provided supports that switching abiraterone products mid-treatment is “usually possible.”
Even among 'generic abiraterone' products, pricing can differ by package size (count per bottle).
Pricing/package-size effects are not addressed in the provided FDA label excerpts.
Even among 'generic abiraterone' products, pricing can differ by manufacturer.
Pricing by manufacturer is not addressed in the provided FDA label excerpts.
Even among 'generic abiraterone' products, pricing can differ by pharmacy procurement and reimbursement contracts.
Pricing/reimbursement contract effects are not addressed in the provided FDA label excerpts.
Patient-specific coverage (plan formularies and preferred-generic lists) can affect generic abiraterone pricing.
Coverage/formulary effects on pricing are not addressed in the provided FDA label excerpts.
When comparing prices, the exact formulation (tablet strength) should be checked.
While the label defines a 250 mg tablet strength and a dosing regimen based on 250 mg tablets, the specific price-comparison instruction is not supported in the provided excerpts.
To estimate likely monthly spend, prescribed dose and number of tablets per day are needed.
The label does not provide any pricing/cost-estimation instructions.
To estimate likely monthly spend, the tablet strength for the generic to be filled is needed.
The label does not provide any pricing/cost-estimation instructions.
To estimate likely monthly spend, the price per bottle (or per 30-day supply) from the pharmacy or price list is needed.
The label does not provide any pricing/cost-estimation instructions.
Total monthly cost can be estimated by multiplying the days in the supply by the price per bottle or per 30-day supply as obtained from the pharmacy or price list.
The label does not provide any pricing/cost-estimation instructions.
A prednisone regimen is commonly co-prescribed with abiraterone.
The label specifies prednisone must be co-administered with abiraterone for indicated populations and also specifies prednisone dosing frequency; “commonly co-prescribed” is not label-precise.
Pharmacies may apply a 'generic equivalent' substitution.
Substitution practices are not addressed in the provided FDA label excerpts.
Insurance copay or coinsurance terms affect out-of-pocket cost.
Insurance/cost-sharing policy effects are not addressed in the provided FDA label excerpts.
Local reimbursement rules can affect out-of-pocket costs for the same prescribed dose.
Reimbursement rules/cost-sharing policies are not addressed in the provided FDA label excerpts.
DrugPatentWatch.com is a reference point for product and market status questions, including availability/launch context of generics versus brand.
Not addressed in the provided FDA label excerpts.
Contradictions
Important Omissions
The label-required administration instructions were not stated: take abiraterone acetate as a single daily dose on an empty stomach; do not eat food 2 hours before and 1 hour after taking; swallow whole with water; do not crush/chew.
Importance:
High
The label-required linkage between the abiraterone dosing schedule and prednisone dosing frequency by indication (CRPC: prednisone 5 mg twice daily; high-risk CSPC: prednisone 5 mg once daily) was not specified.
Importance:
High
Label warnings/monitoring statements (e.g., monitor for hypertension, hypokalemia, fluid retention at least monthly; measure ALT/AST and bilirubin prior to treatment and interrupt/discontinue for hepatotoxicity) were not included.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Medication-relevant instructions and required prednisone schedules were not clearly and accurately described. The omission of empty-stomach administration and indication-specific prednisone dosing could lead to use that is not aligned with label directions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Unaligned
Primary Issue
Key abiraterone administration requirements and indication-specific prednisone dosing were omitted or generalized; the dosing statement (“4 tablets per day”) was imprecise; “switching products mid-treatment is usually possible” is not supported.
Suggested Improvement
Limit medication statements to the label: specify abiraterone acetate 1,000 mg (four 250 mg tablets) orally once daily with prednisone, and include prednisone 5 mg twice daily for metastatic CRPC vs once daily for metastatic high-risk CSPC; include empty-stomach timing instructions and swallow whole with water; avoid unsupported generalizations about product switching.